Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anisomelic acid
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Anisomelic acid is a **macrocyclic cembranolide terpenoid** with the molecular formula C20H26O4 and a molecular weight of about 330.4 g/mol[1][2][4]. It is isolated principally from *Anisomeles malabarica* and *Anisomeles indica* and is known for its **cytotoxic, anti-cancer, and antiviral properties**[1][3][6]. Mechanistically, anisomelic acid induces **apoptosis and DNA damage** in cancer cell lines, reducing cell viability and promoting cell death with observed potential in breast and cervical cancer models[1]. Recent studies show **oral antiviral activity against SARS-CoV-2 in mice**, with in vitro potency comparable to remdesivir, highlighting interest in infectious disease applications[3]. Anisomelic acid is investigated for drug development both as a natural product and through semisynthetic routes from costunolide[3].
- Other names
- (6E,10Z,14Z)-6,14-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,12,13,15a-octahydrocyclotetradeca[b]furan-10-carboxylic acid59632-76-7DTXSID20418461DTXSID-20418461DTXSID 20418461
02
Targets
TMPRSS2 (Transmembrane protease serine 2)CTSB (Cathepsin B)CTSL (Cathepsin L)NRP1 (Neuropilin-1)
Beyond the preview
Go deeper on anisomelic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anisomelic acid.